香连联合埃索美拉唑治疗非幽门螺杆菌相关难治性消化性溃疡

Effect of xianglian combined with esomeprazole for non-Helicobactor pylori related refractory peptic ulcer

目的:探讨香连联合埃索美拉唑治疗非幽门螺杆菌相关难治性消化性溃疡的疗效和安全性。方法:47例非幽门螺杆菌相关性难治性溃疡接受埃索美拉唑治疗(埃索美拉唑组),另外47例接受埃索美拉唑+香连治疗(埃索美拉唑+香连组)。评价两组药物对患者临床症状、内镜下溃疡改善和安全性。结果:共有90例难治性消化性溃疡患者完成试验(每组45例)。埃索美拉唑+香连组在中上腹痛、上腹饱胀、症状总积分、内镜缓解率和愈合率上优于埃索美拉唑组(P<0.05),而在反酸、嗳气和烧心上两组差异无统计学意义(P>0.05)。安全性上二者亦无显著差异(P>0.05)。结论:香连联合埃索美拉唑可有效治疗非幽门螺杆菌相关性难治性消化性溃疡,香连为该类溃疡的辅助治疗提供了新的选择。

Objective To explore the effect and safety of xianglian combined with esomeprazole for nonHelicobactor pylori related refractory peptic ulcer. Methods 94 patients with non-Helicobactor t）ylori related refractory peptic ulcer were assigned to receive esomeprazole or esomeprazole plus xianglian treatment （47 patients each group）. Symptom relief and ulcer improvement in patients in the two groups were compared. Results Relief of epigastric pain and epigastric satiety, total symptom scores, ulcer relief and cure rate under endoscope in esomeprazole plus xianglian group were significantly higher than those in esomeprazole group. There were no significant difference in remission of acid regurgitation, eructation, heartburn, and safety in the two groups. Couclusiou Xianglian combined with esomeprazole can effectively cure the non-Helicobactor pylori related refractory peptic ulcer.